Evaxion Biotech A/S(EVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EVAX Evaxion Biotech A/S

Pre-Mkt 03-19 05:33:44 EDT

3.78

-0.05

-1.31%

High4.02	Low3.66	Vol51.13K
Open3.89	D1 Closing3.83	Amplitude9.40%
Mkt Cap31.38M	Tradable Cap20.91M	Total Shares8.30M
T/O195.06K	T/O Rate0.92%	Tradable Shares5.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EVAX","market":"US","secType":"STK","nameCN":"Evaxion Biotech A/S","latestPrice":3.78,"timestamp":1773864000000,"preClose":3.83,"halted":0,"volume":51125,"delay":0,"changeRate":-0.013054830287206335,"floatShares":5531900,"shares":8302700,"eps":-1.202691,"marketStatus":"Pre-Mkt","change":-0.05,"latestTime":"03-19 05:33:44 EDT","open":3.89,"high":4.02,"low":3.66,"amount":195061.0653,"amplitude":0.093995,"askPrice":4.88,"askSize":100,"bidPrice":3.05,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.202691,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773927000000},"marketStatusCode":1,"adr":0,"adrRate":50,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":3.78,"postHourTrading":{"tag":"盘后","latestPrice":3.78,"preClose":3.78,"latestTime":"16:10 EDT","volume":5,"amount":18.9,"timestamp":1773864604921,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9343700179100083,"impliedVol":2.1042,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/EVAX","defaultTab":"news","newsList":[{"id":"2620946732","title":"Evaxion A/S Director Marianne Soegaard Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620946732","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620946732?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:10","pubTimestamp":1773882622,"startTime":"0","endTime":"0","summary":"Evaxion filed an initial statement of beneficial ownership on March 18, 2026, naming Marianne Soegaard as a director. The filing reported 3,361,687 ordinary shares held directly. It also reported 238,971 ordinary shares held indirectly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL43Rqsl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"gpt_icon":0},{"id":"2620943412","title":"Evaxion A/S files initial beneficial ownership statement for Chief AI Officer Andreas Holm Mattsson","url":"https://stock-news.laohu8.com/highlight/detail?id=2620943412","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620943412?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:09","pubTimestamp":1773882576,"startTime":"0","endTime":"0","summary":"Evaxion reported an initial statement of beneficial ownership for Andreas Holm Mattsson, its Chief AI Officer. The filing listed 1,382,395 ordinary shares held directly. It also reported 4,142,521 ordinary shares held indirectly through Mattsson Holding af 2008 ApS. The filing disclosed warrants exercisable for 645,700 ordinary shares at a conversion price of USD 0.059.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL2l8zMp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"gpt_icon":0},{"id":"2620351294","title":"Evaxion A/S files Form 3 initial beneficial ownership statement for Chief Scientific Officer Birgitte Rono","url":"https://stock-news.laohu8.com/highlight/detail?id=2620351294","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620351294?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:08","pubTimestamp":1773882509,"startTime":"0","endTime":"0","summary":"Evaxion reported an initial statement of beneficial ownership for Birgitte Rono, Chief Scientific Officer, dated 03/18/2026. Rono reported direct ownership of 36,765 ordinary shares. Rono also reported warrants for 36,765 ordinary shares at an exercise price of USD 0.74. Rono reported additional warrants for 125,000 ordinary shares at an exercise price of USD 0.07.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL8KZDrN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"gpt_icon":0},{"id":"2620294337","title":"Evaxion A/S Director Lars Holtug Files Initial Statement of Beneficial Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2620294337","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620294337?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:07","pubTimestamp":1773882465,"startTime":"0","endTime":"0","summary":"Evaxion reported an initial statement of beneficial ownership for director Lars Holtug dated March 18, 2026. The filing listed 258,029 ordinary shares beneficially owned indirectly. It also reported indirect warrants for 73,529 ordinary shares at an exercise price of USD 0.74. The filing reported indirect warrants for 92,250 ordinary shares at an exercise price of USD 0.06. It also listed direct warrants for 25,000 ordinary shares at an exercise price of USD 0.07.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL42s1Gn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"gpt_icon":0},{"id":"2620329433","title":"Evaxion A/S CEO Helen Katrina Tayton-Martin files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620329433","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620329433?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:06","pubTimestamp":1773882419,"startTime":"0","endTime":"0","summary":"Evaxion filed an initial statement of beneficial ownership naming Helen Katrina Tayton-Martin as chief executive officer. The filing reported 2,286,150 ordinary shares held indirectly. It also reported warrants for 2,500,000 ordinary shares at an exercise price of USD 0.12.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6cCzGH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"gpt_icon":0},{"id":"2620405856","title":"Evaxion to Present New AI-Driven Cancer Vaccine Data at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405856","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405856?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:57","pubTimestamp":1773781047,"startTime":"0","endTime":"0","summary":"An update from Evaxion Biotech ( ($EVAX) ) is now available. Evaxion A/S, a Danish clinical-stage TechBio firm focused on AI-designed cancer and in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evaxion-to-present-new-ai-driven-cancer-vaccine-data-at-aacr-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evaxion-to-present-new-ai-driven-cancer-vaccine-data-at-aacr-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AI","BK4023","BK4543","BK4551","BK4585","BK4587","BK4528","BK4588","BK4581","BK4139","AIYY","XBI","EVAX"],"gpt_icon":0},{"id":"2620038244","title":"Evaxion to present two abstracts and attend AACR Oncology Industry Partnering event","url":"https://stock-news.laohu8.com/highlight/detail?id=2620038244","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620038244?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:30","pubTimestamp":1773779440,"startTime":"0","endTime":"0","summary":"Evaxion will present two posters at the AACR Annual Meeting in San Diego on April 22, 2026, from 9am-12pm CST. One poster covers new biomarker and immunogenicity data for the personalized cancer vaccine EVX-01 in advanced melanoma. The second poster presents data on using the AI-Immunology platform to identify endogenous retrovirus-derived neoantigens for a personalized glioblastoma vaccine strategy. Evaxion will also participate in the AACR Oncology Industry Partnering event ahead of the annual meeting.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL2knPl7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4588","SG9999014021.USD","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","LU2095319765.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4585","BK4112","LU0314104364.USD","EVAX","IE00BGHQF748.EUR","BK4139","IE00BN0W2T93.GBP"],"gpt_icon":0},{"id":"2619462654","title":"European Equities Traded in the US as American Depositary Receipts Higher Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2619462654","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619462654?lang=en_us&edition=fundamental","pubTime":"2026-03-16 23:22","pubTimestamp":1773674559,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were rising on Monday morning, up 1.7% to 1,741.84 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by solar energy technology company Turbo Energy  and clinical stage biotechnology company Abivax , which rose 7.5% and 5.7% respectively. They were followed by telecommunications and consumer electronics company Nokia , which added 4.3%.The decliners from continental Europe were led by biotech company Evaxion  and construction engineering company Cadeler , which fell 7.3% and 4% respectively. They were followed by clinical stage biopharmaceutical company DBV Technologies , which was down 0.8%.From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics  and cruise line operator Carnival , which rose 5.9% and 3.8% respectively.The decliners from the UK and Ireland were led by oncology biotech company Akari Therapeutics  and clinical stage biotech company Biode","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLN","BK4096","EVAX","CUK","BDRX","NOK","LNOK","BK4547","AFG","BK4007","BK4107","IE00BMPRXN33.USD","BK4020","ABVX","BK4117","AKTX","DBVT","IE00BMPRXR70.SGD","TURB","BK4142","CDLR","BK4129","BK4139"],"gpt_icon":0},{"id":"2619711926","title":"European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2619711926","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619711926?lang=en_us&edition=fundamental","pubTime":"2026-03-14 00:11","pubTimestamp":1773418305,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower late Friday morning, declining 0.29% to 1,721.83 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion  and biopharmaceutical company Cellectis , which rose 8.3% and 7.8% respectively. They were followed by telecommunications Nokia  and medical device maker EDAP , which increased 3.6% and 2.9% respectively.The decliners from continental Europe were led by 3D printer company Materialise  and accommodations booking site trivago , which fell 2.2% and 2% respectively. They were followed by lender ING   biopharmaceutical company Grifols , which were down 1.8% and 1.7% respectively.The gainers from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group  and cruise line operator Carnival , which advanced 3.2% and 1.1% respectively. They were followed by telecommunications operator Vodafone  and alcoholic beverage company Diageo , which were u","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4142","BK7511","IE00BMPRXR70.SGD","BK7141","CUK","MTLS","BK7507","CLLS","LU0300736062.USD","BK4547","BK4082","BK4532","LNOK","VOD","BK4007","DEO","BDRX","ING.AU","AFG","ING","BK7505","MREO","BHP","BK4168","GRFS","BK4132","EVAX","LU0300736492.USD","BK4505","IE00BMPRXN33.USD","BK4107","BHP.AU","NOK","BK4588","BK7095","BCYC","BK4546","BK4559","AKTX","BK4077","DGE.UK","BK4020","BK4117","BK4585","EDAP","BK4023","TRVG","BK4207","BK4169"],"gpt_icon":0},{"id":"2618588301","title":"European Equities Traded in US as ADRs Slump in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2618588301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618588301?lang=en_us&edition=fundamental","pubTime":"2026-03-12 23:10","pubTimestamp":1773328202,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts slumped late Thursday morning with the S&P Europe Select ADR Index declining 1.9% to 1,723.21.From continental Europe, the gainers were led by biotech firm Evaxion  and telecommunications company Nokia , which climbed 6.4% and 3.5%, respectively. They were followed by 3D printer company Materialise  and petroleum refiner Equinor , which advanced 3.4% and 2.3%, respectively.The decliners from continental Europe were led by lender Banco Bilbao Vizcaya Argentaria  and biopharmaceutical company Cellectis , which dropped 6% and 5.5%, respectively. They were followed by lenders Banco Santander  and ING , which lost 4.1% and 3.9%, respectively.From the UK and Ireland, the gainers were led by biopharmaceutical company Akari Therapeutics  and oil and gas company BP , which rose 1.9% and 1.3%, respectively. They were followed by utility company National Grid  and oil and gas company Shell , which were up 1.2% and 1.1%, respective","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4546","BK4532","CLLS","EVAX","BBVA","BK4547","HSBC","BK4588","SAN","LU0278409577.USD","NGG","BPH","LU0310800965.SGD","LU0320765646.SGD","LU2236285917.USD","BK4521","CUK","LNOK","BK7505","LU0072461881.USD","ING.AU","LU0128525689.USD","LU0300736492.USD","BK4207","EQNR","IE00BMPRXR70.SGD","BP","LU0300736062.USD","HSBH","LU0098860793.USD","BK7141","NOK","BCS","AUTL","BK4007","SHEL","BK4585","ING","LU1267930227.SGD","SAN.AU","SHEH","BK4020","BK4208","AKTX","LU1829250122.USD","BK7142","BK4142","MTLS","BK4023"],"gpt_icon":0},{"id":"2618296392","title":"Evaxion: Strengthened Cash Runway and Advancing AI-Immunology Pipeline Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618296392","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618296392?lang=en_us&edition=fundamental","pubTime":"2026-03-11 02:35","pubTimestamp":1773167722,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Michael Okunewitch has maintained their bullish stance on EVAX stock, giving a Buy rating yesterday. Michael Okunewitch has giv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/evaxion-strengthened-cash-runway-and-advancing-ai-immunology-pipeline-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/evaxion-strengthened-cash-runway-and-advancing-ai-immunology-pipeline-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EVAX"],"gpt_icon":0},{"id":"2618195724","title":"Evaxion Initiated at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2618195724","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618195724?lang=en_us&edition=fundamental","pubTime":"2026-03-11 01:00","pubTimestamp":1773162000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 13:00 ET (17:00 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"gpt_icon":0},{"id":"2618672151","title":"Analysts Conflicted on These Healthcare Names: Hims & Hers Health (HIMS), US Physical Therapy (USPH) and Evaxion Biotech (EVAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618672151?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:30","pubTimestamp":1773088216,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS – Research Report), US Physical Therapy ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-hims-hers-health-hims-us-physical-therapy-usph-and-evaxion-biotech-evax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-hims-hers-health-hims-us-physical-therapy-usph-and-evaxion-biotech-evax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HIMZ","USPH","LU0128526141.USD","LU0012050646.USD","LU0106261612.USD","BK4581","LU0029874061.USD","BK4588","BK4585","XBI","HIMY","BK4196","BK4139","BK4185","HIMS","EVAX","BK4137","HIYY","HMYY","LABU"],"gpt_icon":0},{"id":"2618228674","title":"Evaxion Biotech assumed with a Buy at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2618228674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618228674?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:11","pubTimestamp":1773087073,"startTime":"0","endTime":"0","summary":"JonesResearch assumed coverage of Evaxion Biotech (EVAX) with a Buy rating and $10 price target The firm says the company uses its AI-driven platfo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-assumed-with-a-buy-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evaxion-biotech-assumed-with-a-buy-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4528","BK4543","AI","EVAX","BK4139","BK4588","BK4587","BK4585","BK4023","AIYY"],"gpt_icon":0},{"id":"2618209486","title":"European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2618209486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618209486?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:30","pubTimestamp":1773070209,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking slightly lower late Monday morning, declining 0.30% to 1,727.53 on the S&P Europe Select ADR Index.From continental Eur","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4142","E","LU0154236417.USD","BK4077","NVOH","DBVT","BK4082","BK4599","BK7119","IE00BKVL7J92.USD","NCNA","BK4007","BUD","CRTO","LU1093756325.SGD","BK7104","LU1093756168.USD","AUTL","AFG","TRVG","TRIB","IE00BZ1G4Q59.USD","BCYC","NVO.AU","BK4532","SLN","BK4585","BK4588","BK4107","NVOX","BK4158","MREO","IE00BFMHRM44.USD","BK4117","BK4505","CUK","EQNR","BUD.AU","BK4201","BK4139","BK4009","NVO","BDRX","EVAX"],"gpt_icon":1},{"id":"2618647326","title":"Evaxion Price Target Maintained With a $16.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647326","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647326?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:27","pubTimestamp":1773052020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 06:27 ET (10:27 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVAX"],"gpt_icon":0},{"id":"2617216215","title":"European Equities Traded in the US as American Depositary Receipts Slide in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2617216215","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617216215?lang=en_us&edition=fundamental","pubTime":"2026-03-06 00:05","pubTimestamp":1772726723,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were sliding late Thursday morning, down 1.31% to 1,760.75 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion  and internet browser company Opera , which rose 4.3% and 4.2%, respectively. They were followed by biopharmaceutical company Cellectis  and internet advertising firm Criteo , which were up 2.3% and 1.9%, respectively.The decliners from continental Europe were led by telecommunications company Nokia  and healthcare tech company Philips , which dropped 3.8% and 3.7%, respectively. They were followed by biopharmaceutical company argenx  and lender Banco Santander , which lost 3.6% and 2.8%, respectively.From the UK and Ireland, the gainers were led by biotech company Trinity Biotech  and communications firm WPP , which advanced 6.7% and 4.4%, respectively. They were followed by biopharmaceutical company Akari Therapeutics  and software firm Endava , which incre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJJMRZ35.SGD","LU0889565916.HKD","LU2324357040.USD","SNN","BTI.AU","LU1983260115.SGD","EVAX","CRTO","DAVA.AU","BK4134","BK4020","LU0648005311.SGD","LU0320765992.SGD","NOK","IE00BJT1NW94.SGD","BK7142","AUTL","SAN.AU","PHG","LU2543165471.USD","IE00BFMHRM44.USD","SAN","IE0034235188.USD","BK4588","LU0109394709.USD","SLN","BK4117","BK4107","LNOK","BK4139","ARGX","AFG","DAVA","TRIB","IE00B4R5TH58.HKD","LU0084288595.USD","BK4009","OPRA","IE00BMPRXN33.USD","BK4585","BTI","IE00BFTCPJ56.SGD","WPP","WPP.AU","AKTX","CLLS","BK7062","IE00BMPRXR70.SGD","IE00B2B36J28.USD","IE0002141913.USD"],"gpt_icon":0},{"id":"2617290345","title":"Evaxion A/S reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2617290345","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617290345?lang=en_us&edition=fundamental","pubTime":"2026-03-05 23:52","pubTimestamp":1772725965,"startTime":"0","endTime":"0","summary":"Evaxion A/S reports results for the quarter ended December 31 - Earnings SummaryEvaxion A/S EVAX.OQ reported a quarterly adjusted loss of 100 cents per share for the quarter ended December 31, higher ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL8N3ZT1Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"gpt_icon":0},{"id":"2617261125","title":"Evaxion Posts Transformational 2025, Extends Cash Runway Into 2027 on MSD Deal and Vaccine Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2617261125","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617261125?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:55","pubTimestamp":1772722559,"startTime":"0","endTime":"0","summary":"Evaxion Biotech ( ($EVAX) ) has provided an update. On March 5, 2026, Evaxion reported that 2025 was a transformational year marked by strategic, s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evaxion-posts-transformational-2025-extends-cash-runway-into-2027-on-msd-deal-and-vaccine-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evaxion-posts-transformational-2025-extends-cash-runway-into-2027-on-msd-deal-and-vaccine-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU2065732104.USD","PRGS","BK4588","BK4097","EVAX","LABU","BK4139"],"gpt_icon":0},{"id":"2617525248","title":"Cancer drug developer Evaxion Biotech's FY25 net loss narrows on higher revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2617525248","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617525248?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:41","pubTimestamp":1772721713,"startTime":"0","endTime":"0","summary":"Cancer drug developer Evaxion Biotech's FY25 net loss narrows on higher revenueOverviewDenmark TechBio firm's 2025 net loss narrows to $7.7 mln, driven by higher revenue and lower operating expenses20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL1N3ZT0SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVAX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.evaxion.ai","stockEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":0.1317},{"period":"3month","weight":-0.3426},{"period":"6month","weight":0.2249},{"period":"1year","weight":1.0432},{"period":"ytd","weight":-0.2075}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.312391},{"month":2,"riseRate":0,"avgChangeRate":-0.075072},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.064259},{"month":4,"riseRate":0.6,"avgChangeRate":0.075553},{"month":5,"riseRate":0.4,"avgChangeRate":0.067918},{"month":6,"riseRate":0.2,"avgChangeRate":-0.044814},{"month":7,"riseRate":0.4,"avgChangeRate":0.060856},{"month":8,"riseRate":0.6,"avgChangeRate":-0.04913},{"month":9,"riseRate":1,"avgChangeRate":0.19717},{"month":10,"riseRate":0.4,"avgChangeRate":0.102065},{"month":11,"riseRate":0.2,"avgChangeRate":-0.236379},{"month":12,"riseRate":0,"avgChangeRate":-0.21322}],"exchange":"NASDAQ","name":"Evaxion Biotech A/S","nameEN":"Evaxion Biotech A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Evaxion Biotech A/S(EVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Evaxion Biotech A/S(EVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Evaxion Biotech A/S,EVAX,Evaxion Biotech A/S股票,Evaxion Biotech A/S股票老虎,Evaxion Biotech A/S股票老虎国际,Evaxion Biotech A/S行情,Evaxion Biotech A/S股票行情,Evaxion Biotech A/S股价,Evaxion Biotech A/S股市,Evaxion Biotech A/S股票价格,Evaxion Biotech A/S股票交易,Evaxion Biotech A/S股票购买,Evaxion Biotech A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Evaxion Biotech A/S(EVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Evaxion Biotech A/S(EVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction